六氢大麻酚（HHC）在爱尔兰的使用和危害：2024年欧洲毒品网络调查的新发现。

IF 4.4 2区医学 Q1 SUBSTANCE ABUSE

International Journal of Drug Policy Pub Date : 2025-09-18 DOI:10.1016/j.drugpo.2025.105011

Deirdre Mongan , Nicki Killeen , Seán R. Millar , João Matias , Eamon Keenan , Brian Galvin

{"title":"六氢大麻酚（HHC）在爱尔兰的使用和危害：2024年欧洲毒品网络调查的新发现。","authors":"Deirdre Mongan , Nicki Killeen , Seán R. Millar , João Matias , Eamon Keenan , Brian Galvin","doi":"10.1016/j.drugpo.2025.105011","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Hexahydrocannabinol (HHC) is a semi-synthetic cannabinoid which was marketed and sold openly in Ireland as a legal alternative to cannabis products until it was controlled in July 2025. There have been reports of psychotic illness precipitated by HHC use. Consequently, there are fears that HHC may become a public health issue. This study’s aim was to measure the extent of HHC use and patterns of use among adults in Ireland who use drugs.</div></div><div><h3>Methods</h3><div>Data on HHC use in Ireland were collected from participants aged 18+ years (<em>N</em> = 2314) who had used drugs in the previous year via the 2024 European Web Survey on Drugs, which included questions on frequency of use; reasons for starting and using; how HHC was obtained and administration method; and harms arising from use.</div></div><div><h3>Results</h3><div>In total, 36.2 % reported lifetime HHC use, 33.5 % last-year use, and 17.8 % last-month use. The primary motive for first using HHC was its easy availability in stores and the main source of HHC reported was a high street shop (62.4 %). Negative consequences arising from HHC use were reported by 89.9 % of respondents: 14.7 % reported anxiety or panic reactions, while 13.4 % felt faint or dizzy and 11.9 % reported dissociation or depersonalisation. Hallucinations or psychosis were reported by 3.9 %, depression by 3.6 %, and withdrawal symptoms by 3.2 %.</div></div><div><h3>Conclusions</h3><div>These data suggest that HHC has become a prominent feature of the Irish drug landscape. Given its harm potential, it will be important to monitor HHC use and related health harms.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"145 ","pages":"Article 105011"},"PeriodicalIF":4.4000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hexahydrocannabinol (HHC) use and harms in Ireland: New findings from the 2024 European Web Survey on Drugs\",\"authors\":\"Deirdre Mongan , Nicki Killeen , Seán R. Millar , João Matias , Eamon Keenan , Brian Galvin\",\"doi\":\"10.1016/j.drugpo.2025.105011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Hexahydrocannabinol (HHC) is a semi-synthetic cannabinoid which was marketed and sold openly in Ireland as a legal alternative to cannabis products until it was controlled in July 2025. There have been reports of psychotic illness precipitated by HHC use. Consequently, there are fears that HHC may become a public health issue. This study’s aim was to measure the extent of HHC use and patterns of use among adults in Ireland who use drugs.</div></div><div><h3>Methods</h3><div>Data on HHC use in Ireland were collected from participants aged 18+ years (<em>N</em> = 2314) who had used drugs in the previous year via the 2024 European Web Survey on Drugs, which included questions on frequency of use; reasons for starting and using; how HHC was obtained and administration method; and harms arising from use.</div></div><div><h3>Results</h3><div>In total, 36.2 % reported lifetime HHC use, 33.5 % last-year use, and 17.8 % last-month use. The primary motive for first using HHC was its easy availability in stores and the main source of HHC reported was a high street shop (62.4 %). Negative consequences arising from HHC use were reported by 89.9 % of respondents: 14.7 % reported anxiety or panic reactions, while 13.4 % felt faint or dizzy and 11.9 % reported dissociation or depersonalisation. Hallucinations or psychosis were reported by 3.9 %, depression by 3.6 %, and withdrawal symptoms by 3.2 %.</div></div><div><h3>Conclusions</h3><div>These data suggest that HHC has become a prominent feature of the Irish drug landscape. Given its harm potential, it will be important to monitor HHC use and related health harms.</div></div>\",\"PeriodicalId\":48364,\"journal\":{\"name\":\"International Journal of Drug Policy\",\"volume\":\"145 \",\"pages\":\"Article 105011\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Drug Policy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S095539592500307X\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"SUBSTANCE ABUSE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Drug Policy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S095539592500307X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}

引用次数: 0

摘要

背景：六氢大麻酚（HHC）是一种半合成大麻素，在爱尔兰作为大麻产品的合法替代品公开销售，直到2025年7月受到管制。曾有因使用HHC而诱发精神病的报道。因此，人们担心HHC可能会成为一个公共卫生问题。这项研究的目的是衡量爱尔兰成年人吸毒的HHC使用程度和使用模式。方法：通过2024年欧洲药物网络调查收集爱尔兰18岁以上（N = 2314）的参与者使用HHC的数据，这些参与者在前一年使用过药物，其中包括使用频率的问题；启动和使用的原因；HHC的获取途径和给药方法；以及因使用而产生的危害。结果：报告终生使用HHC者占36.2%，去年使用者占33.5%，上个月使用者占17.8%。首次使用HHC的主要动机是易于在商店获得，报告的HHC主要来源是高街商店（62.4%）。89.9%的受访者报告了使用HHC产生的负面后果：14.7%报告了焦虑或恐慌反应，13.4%感到头晕或头晕，11.9%报告了精神分裂或人格解体。幻觉或精神病占3.9%，抑郁症占3.6%，戒断症状占3.2%。结论：这些数据表明，HHC已成为爱尔兰毒品景观的一个突出特征。鉴于其潜在危害，监测六氯环己烷的使用和相关的健康危害将是重要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Hexahydrocannabinol (HHC) use and harms in Ireland: New findings from the 2024 European Web Survey on Drugs

Background

Hexahydrocannabinol (HHC) is a semi-synthetic cannabinoid which was marketed and sold openly in Ireland as a legal alternative to cannabis products until it was controlled in July 2025. There have been reports of psychotic illness precipitated by HHC use. Consequently, there are fears that HHC may become a public health issue. This study’s aim was to measure the extent of HHC use and patterns of use among adults in Ireland who use drugs.

Methods

Data on HHC use in Ireland were collected from participants aged 18+ years (N = 2314) who had used drugs in the previous year via the 2024 European Web Survey on Drugs, which included questions on frequency of use; reasons for starting and using; how HHC was obtained and administration method; and harms arising from use.

Results

In total, 36.2 % reported lifetime HHC use, 33.5 % last-year use, and 17.8 % last-month use. The primary motive for first using HHC was its easy availability in stores and the main source of HHC reported was a high street shop (62.4 %). Negative consequences arising from HHC use were reported by 89.9 % of respondents: 14.7 % reported anxiety or panic reactions, while 13.4 % felt faint or dizzy and 11.9 % reported dissociation or depersonalisation. Hallucinations or psychosis were reported by 3.9 %, depression by 3.6 %, and withdrawal symptoms by 3.2 %.

Conclusions

These data suggest that HHC has become a prominent feature of the Irish drug landscape. Given its harm potential, it will be important to monitor HHC use and related health harms.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Drug Policy SUBSTANCE ABUSE-

CiteScore

7.80

自引率

11.40%

发文量

307

审稿时长

62 days

期刊介绍： The International Journal of Drug Policy provides a forum for the dissemination of current research, reviews, debate, and critical analysis on drug use and drug policy in a global context. It seeks to publish material on the social, political, legal, and health contexts of psychoactive substance use, both licit and illicit. The journal is particularly concerned to explore the effects of drug policy and practice on drug-using behaviour and its health and social consequences. It is the policy of the journal to represent a wide range of material on drug-related matters from around the world.